Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Sandu Pharmaceuticals Ltd. shows potential in the context of profitability and growth compared to its peers, although its financial metrics indicate it is underperforming in valuation and efficiency. Companies like Cipla and Dr. Reddy's demonstrate stronger profitability and valuation attractiveness, while Sandu's low debt level is a positive aspect in a sector where many companies exhibit higher leverage.
Strong revenue growth of 13.28% YoY and the lowest PE ratio among peers, indicating good valuation.
High ROE of 21.76% and a very low PE of 15.50, making it an attractive investment.
Exceptional revenue growth of 18.12% YoY and solid profitability metrics.